tovorafenib   Click here for help

GtoPdb Ligand ID: 9977

Synonyms: BIIB024 | example 10Da [US20090036419] | MLN-2480 | MLN2480 | TAK-580 | TAK580
PDB Ligand
Compound class: Synthetic organic
Comment: TAK-580 (MLN2480) is an investigational pan-RAF kinase inhibitor that was developed for anti-tumour potential against solid tumours, including gliomas, and common adult RAF mutant tumours (harbouring BRAF and CRAF fusions and mutations) that metastasise to the brain. It has been optimised for CNS penetration [2]. The chemical structure is claimed as example 10Da in patent US20090036419A1 [1]. Day One Biopharmaceuticals licensed this inhibitor from Sunesis Pharma in 2019, at which point it was re-named DAY101. The chemical structure of TAK-580 is identical to that which was submitted to the WHO for the INN tovorafenib (proposed INN list 126, Jan 2022).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 164.02
Molecular weight 505.01
XLogP 1.82
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(c1ncc(s1)C(=O)Nc1ncc(c(c1)C(F)(F)F)Cl)NC(=O)c1ncnc(c1Cl)N
Isomeric SMILES C[C@H](c1ncc(s1)C(=O)Nc1ncc(c(c1)C(F)(F)F)Cl)NC(=O)c1ncnc(c1Cl)N
InChI InChI=1S/C17H12Cl2F3N7O2S/c1-6(28-15(31)12-11(19)13(23)27-5-26-12)16-25-4-9(32-16)14(30)29-10-2-7(17(20,21)22)8(18)3-24-10/h2-6H,1H3,(H,28,31)(H2,23,26,27)(H,24,29,30)/t6-/m1/s1
InChI Key VWMJHAFYPMOMGF-ZCFIWIBFSA-N
Bioactivity Comments
TAK-580 functions as an effective inhibitor of BRAFV600E and KIAA1549:BRAF, a truncation/fusion BRAF oncoprotein which is active as a dimer and drives the most common form of pediatric low-grade astrocytomas [2]. It has low potency towards wild type BRAF, but is more potent against the kinase activities of BRAFV600E (IC50 248 nM) and KIAA1549:BRAF (IC50 190 nM).
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
B-Raf proto-oncogene, serine/threonine kinase Hs Inhibitor Inhibition 5.7 pIC50 - 2
pIC50 5.7 (IC50 1.895x10-6 M) [2]